SCHEMBL22862586

SCHEMBL22862586

Cn1c(=O)n(C)c2cc(CC(=O)NN)ccc21

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 6/20 0.50
▸ ALDH1A1 P00352 4/20 0.50
▸ HSD17B10 Q99714 2/20 0.50
▸ BRPF1 P55201 2/20 0.50
▸ LMNA P02545 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ BRD4 O60885 1/20 0.50
▸ RAB9A P51151 1/20 0.48
▸ POLB P06746 2/20 0.48
▸ TP53 P04637 1/20 0.48
▸ GAA P10253 1/20 0.47
▸ AOC2 O75106 3/20 0.47
▸ TSHR P16473 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ GLA P06280 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22862697 0.81 ALDH1A1 (0.65) SMN1; SMN2ALDH1A1HSD17B10BRPF1LMNA
SCHEMBL5837254 0.81 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1HSD17B10BRPF1LMNA
SCHEMBL29490211 0.80 TSHR (0.59) SMN1; SMN2ALDH1A1HSD17B10BRPF1LMNA
SCHEMBL22862695 0.80 TSHR (0.59) SMN1; SMN2ALDH1A1HSD17B10BRPF1LMNA
SCHEMBL32685198 0.76 POLB (0.55) SMN1; SMN2ALDH1A1HSD17B10BRPF1LMNA
SCHEMBL13156353 0.75 POLB (0.53) SMN1; SMN2ALDH1A1HSD17B10BRPF1LMNA
SCHEMBL7479892 0.75 POLB (0.53) SMN1; SMN2ALDH1A1HSD17B10BRPF1LMNA
Hydrochloric Acid SCHEMBL31737865 0.74 POLB (0.51) SMN1; SMN2ALDH1A1HSD17B10BRPF1LMNA
SCHEMBL11600370 0.74 ALDH1A1 (0.56) SMN1; SMN2ALDH1A1HSD17B10BRPF1LMNA
SCHEMBL22862558 0.73 POLB (0.54) SMN1; SMN2ALDH1A1HSD17B10BRPF1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220389028-A1 BAX INHIBITORS AND USES THEREOF CASE WESTERN RESERVE UNIVERSITY 2022-12-08 — — US disclosed
WO-2021002986-A2 BAX INHIBITORS AND USES THEREOF CASE WESTERN RESERVE UNIVERSITY (US) 2021-01-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220389028-A1 BAX INHIBITORS AND USES THEREOF BAX, TMBIM6, BCL2 SMN1; SMN2 2633/4885ALDH1A1 4296/4885HSD17B10 2484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback